Healthcare, Pharma & Life Sciences

Shawnee County Jail Opens $21M Behavioral Health Unit

Image
Shawnee County Jail Opens $21M Behavioral Health Unit

Topeka – September 12, 2026 -- A new 60-bed Behavioral Health Unit at the Shawnee County Jail in Topeka, Kansas, opened on August 24 following a three-year, $21 million construction project, expanding specialized care for pretrial detainees with mental health and substance use needs.

VitalCore Health Strategies backs 23,279-square-foot expansion

The addition was built to serve individuals awaiting trial who require mental health treatment, substance use support, suicide prevention, competency restoration, and other specialized services. VitalCore Health Strategies provides healthcare services at the facility under a partnership with the Shawnee County Department of Corrections that began in 2024.

Sectra Shareholders Approve SEK 2.30 Dividend, New Incentive Plan at AGM

Linköping – – September 12, 2026 -- Shareholders of Sectra AB (STO:SECTB) approved a combined dividend of SEK 2.30 per share at the medical imaging IT and cybersecurity company's Annual General Meeting held September 8, 2026.

Sectra sets record date for SEK 2.30 combined payout

The AGM resolved to distribute an ordinary dividend of SEK 1.30 per share plus an extraordinary dividend of SEK 1.00 per share, with remaining funds carried forward. The record date is September 10, 2026, and payment through Euroclear Sweden AB is expected September 15, 2026.

Stanley Cup Visits Riccobene Dental as Firm Marks 26 Years of Growth

Image
Stanley Cup Visits Riccobene Dental as Firm Marks 26 Years of Growth

Garner, N.C. – September 12, 2026 -- The Stanley Cup made a stop at Riccobene Associates Family Dentistry's Garner office last week, marking a milestone celebration for a dental organization that has grown from a single Selma, N.C. practice into a 100-plus location operator across three states.

Founder marks 26 years of expansion from one practice to 100+ locations

Dr. Michael Riccobene founded the organization in 2000 in Selma, North Carolina. It has since grown into a doctor-led, multi-specialty dental group headquartered in Cary, North Carolina, now supporting more than 150 providers, over 1,200 employees, and more than 100 practices across North Carolina, South Carolina, and Virginia.

Base-Editing Therapy Achieves Transfusion Independence Across Ethnicities

Image
Base-Editing Therapy Achieves Transfusion Independence Across Ethnicities

Shanghai – September 12, 2026 -- CorrectSequence Therapeutics (Correctseq) reported that its transformer Base Editor (tBE) therapy CS-101/CS-206 delivered durable clinical remission in patients with sickle cell disease (SCD) and transfusion-dependent β-thalassemia (TDT) across four distinct genetic backgrounds, according to a peer-reviewed study published in Cell Stem Cell on September 7, 2026.

The study, conducted with multiple research institutions, expands on earlier data showing five Chinese TDT patients treated with CS-101 all achieved transfusion independence. The new cohort includes four patients from Nigeria, Laos, Malaysia and Pakistan -- one with SCD and three with TDT -- covering genotypes βS/βS, β0/βE, and two β0/β0 variants with different mutation types.

QuVa Pharma Acquires CAPS' Essential Medication Portfolio

Image
QuVa Pharma Acquires CAPS' Essential Medication Portfolio

Sugar Land, Texas – September 12, 2026 -- QuVa Pharma, Inc. has acquired a range of essential medications from Central Admixture Pharmacy Services, Inc. (CAPS) after CAPS decided to exit the 503B sterile compounding business.

QuVa to phase in acquired products starting later in 2026

QuVa expects to begin introducing selected products from the acquired portfolio in phases later in 2026, with plans to expand its offerings over the following six months. The deal covers critical medication categories including Cardioplegia, Neonatal Starter Bags and Heparin, products used directly in patient care at hospitals nationwide.

Survey: 40% of German Emergency Calls Tied to Care-Access Gaps

Berlin – September 12, 2026 -- More than 40% of unnecessary emergency dispatches in Germany stem from patients' lack of awareness about alternative care options, according to a survey of rescue workers commissioned by the Left party's Bundestag faction, as the federal government advances a reform plan centered on stricter patient triage for the 112 emergency line.

Rescue workers rank ignorance of care alternatives as the top cause of misdirected calls

The survey found that ambulance crews and paramedics identify unfamiliarity with non-emergency care channels -- such as general practitioners or pharmacies -- as the leading driver of avoidable 112 calls, cited in over 40% of responses. Cases range from patients calling about a tick bite to those reporting leg pain that has persisted for three weeks.

ARUP Study: Atypical cfDNA Results Flag Real Diagnoses in 50% of Cases

Image
ARUP Study: Atypical cfDNA Results Flag Real Diagnoses in 50% of Cases

Salt Lake City – September 12, 2026 -- A decade-long study by ARUP Laboratories found that 50% of pregnancies with atypical prenatal cell-free DNA (cfDNA) screening results carried at least one clinically significant abnormality confirmed by follow-up testing, reshaping how providers should respond to inconclusive genetic screens.

ARUP analyzed over 200 atypical cfDNA cases spanning more than 10 years

Researchers reviewed more than 10 years of data and over 200 cases where atypical cfDNA screening results were followed by additional prenatal, postnatal, or maternal testing. The findings, published in Genetics in Medicine, the official journal of the American College of Medical Genetics and Genomics (ACMG), represent what ARUP describes as the largest study of its kind on atypical cfDNA findings.

Unicycive Faces Securities Class Action Over Manufacturing Disclosure Lapses

Image
Unicycive Faces Securities Class Action Over Manufacturing Disclosure Lapses

New York – September 12, 2026 -- Bronstein, Gewirtz & Grossman, LLC has filed a class action lawsuit against Unicycive Therapeutics, Inc. (NASDAQ: UNCY) and certain of its officers, alleging violations of federal securities laws tied to the company's handling of a third-party manufacturing vendor's compliance issues.

Lawsuit covers investors who purchased Unicycive stock between September 12, 2026 and September 12, 2026

The complaint alleges Unicycive failed to inspect or audit its third-party manufacturing vendor's facility for compliance with current good manufacturing practices (cGMP). As a result, the company allegedly lacked a reasonable basis to claim the vendor had remedied deficiencies previously cited by the U.S. Food and Drug Administration.

PROTEOR Launches 'Unleashed' Book Ahead of 2027 Community Impact Push

Image
PROTEOR Launches 'Unleashed' Book Ahead of 2027 Community Impact Push

Las Vegas – September 12, 2026 -- PROTEOR USA is publishing "Unleashed: Real Stories of Strength, Independence, and Community," a 20-story collection centered on individuals with limb loss and limb difference, marking an early step in a broader Community Impact strategy the prosthetics and orthotics maker plans to formalize by 2027.

PROTEOR debuts the book at AOPA's 2026 National Assembly

The title will be introduced at PROTEOR's booth 313 during the 2026 AOPA National Assembly in Las Vegas, with distribution also set through Amazon and BookBaby.

Base-Editing Therapy tBE Delivers Transfusion Independence Across Genetic Backgrounds

Image
Base-Editing Therapy tBE Delivers Transfusion Independence Across Genetic Backgrounds

Shanghai – September 12, 2026 -- CorrectSequence Therapeutics (Correctseq) reported that its transformer Base Editor (tBE) therapy CS-101/CS-206 achieved full transfusion independence or elimination of vaso-occlusive crises (VOC) in four new patients from Nigeria, Laos, Malaysia and Pakistan, expanding on earlier results in five Chinese patients who all reached transfusion independence. The findings, published September 12, 2026 in Cell Stem Cell, cover patients with sickle cell disease (SCD) and transfusion-dependent beta-thalassemia (TDT) carrying distinct genotypes, including βS/βS, β0/βE, and two β0/β0 variants.